智通财经APP讯，科济药业-B(02171)发布公告，本公司若干附属公司与珠海横琴软银欣创股权投资管理企业(有限合伙)(珠海软银欣创)旗下管理的基金(投资者)达成协议(该等协议)。根据该等协议，投资者同意以现金对价人民币8000万元认购优恺泽生物医药(上海)有限公司(优恺泽)的新增注册资本，占优恺泽增资后注册资本的8%(本次增资)。本次增资完成后，本公司于优恺泽的权益将由100% 稀释至92%。
优恺泽是一家在中国内地专注于利用通用型CAR-T细胞疗法治疗血液瘤的新药研发公司。根据该等协议，优恺泽获得本公司治疗多发性骨髓瘤、浆细胞白血病的通用型BCMA CAR-T细胞产品以及治疗B细胞肿瘤的通用型CD19/CD20 CAR-T 细胞产品(不包括治疗自身免疫性疾病的适应证)在中国内地的研发、生产与商业化的独家权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.